WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel
10.3.2026 11:00:00 CET | Business Wire | Press release
WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper
WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel
These initiatives reflect the company’s commitment to advancing women’s health in an area that has historically been under-researched and underrepresented in data, clinical standards, and performance science. Women represent a growing share of new WHOOP members, with 150% year-over-year growth, signaling increasing demand for health insights that account for hormonal dynamics, training response, and long-term health outcomes. Women also engage with WHOOP AI approximately 30% more than male members, reflecting strong demand for intelligent, personalized women’s health support.
“Unlike solutions that focus on isolated conditions or single life stages, WHOOP delivers a connected health experience informed by one of the world’s largest datasets on women’s physiology,” said Alex Vannoni, Head of Healthcare Product at WHOOP. “We’re not just helping women track their cycles. We’re helping them understand how their physiology evolves over time - and giving them tools to act on it.”
WHOOP Advanced Labs: Women’s Health Specialized Panel
The Advanced Labs baseline and new Women’s Health Specialized Panel create a progressive, female-first testing pathway that supports women across all life stages.
The new panel, launching next month, includes critical biomarkers that dive deeper into cycle regulation and hormonal transitions, including perimenopause, thyroid function, nutrient sufficiency, and bone–metabolic resilience. The biomarkers tested are: Anti-Müllerian Hormone (AMH), Progesterone, Prolactin and Thyroid Peroxidase Antibodies (TPOAb), Free T4, Free T3, Leptin, Vitamin B12 (Cobalamin), Folate, Magnesium and Phosphate (as Phosphorus).
By layering lab data on top of continuous wearable metrics and AI-modelling, WHOOP enables members to see how biomarkers correlate with recovery trends, strain tolerance, sleep efficiency, and stress patterns over time - turning static lab results into dynamic insight.
Members will be able to purchase the Women’s Health Specialized Panel via the WHOOP app.
Hormonal Symptom Insights and Predictions
WHOOP is also expanding its Menstrual Cycle Insights and Pregnancy Insights offering, with a new update - Hormonal Symptom Insights and Predictions. Within the WHOOP app, menstruating members will now receive a personalized model of their cycle that adapts over time, based on their unique physiological data and historical patterns.
Within the WHOOP app, members will now have access to key data about their cycle that allows them to accurately adjust their daily routines, fitness regimes, and recovery practices and anticipate potential symptoms rather than simply recording them. This includes access to:
- A dynamic date window for the next period, allowing for more anticipation around the menstrual cycle
- Tracked trends in cycle length, period length, and variability, flagging irregular patterns before larger issues persist
- Analyzed individual symptom patterns to anticipate when symptoms are most likely to occur
As part of the latest Cycle Insights updates, the feature now integrates with WHOOP Advanced Labs. This integration enables WHOOP to deliver personalized biomarker ranges - categorized as ‘optimal,’ ‘sufficient,’ or ‘out of range’ - based on where a member is in their cycle. When a member completes a blood draw, WHOOP automatically applies the appropriate reference range aligned to their recorded cycle phase, ensuring results are interpreted through the lens of their physiology. It’s another example of how women’s unique biology is embedded into every WHOOP product and feature.
Menstrual Cycle White Paper
WHOOP has also published a comprehensive Menstrual Cycle White Paper outlining the research, methodology, and validation behind its modeling approach. The white paper proves how continuous physiological monitoring improves prediction accuracy over time, how the system accounts for variable cycles, perimenopause, and hormonal birth control, and how prediction windows dynamically widen or narrow based on variability.
By bringing continuous, longitudinal visibility to cycle patterns, WHOOP aims to increase health literacy and close a long-standing data gap in women’s health.
“What makes this powerful isn’t any single data point - it’s how the system comes together," said Emily Capodillupo, Senior Vice President of Research, Algorithms, and Data at WHOOP. “Women don’t experience their physiology in silos. Hormones influence sleep, sleep affects recovery, and recovery shapes training response. By modeling these interactions over time - across continuous biometrics, lab data, and behavior - we can deliver guidance that reflects the full system, not just a snapshot.”
With the support of the WHOOP Medical Advisory Board, including Dr. Robin Berzin and Dr. Hazel Wallace, and in tandem with their recent collaboration with Clue, a leader in menstrual and reproductive health, WHOOP will continue to drive innovation in women’s health and deliver on the company’s goal of adding one billion healthy years to the planet.
The Women’s Health Specialized Panel, along with additional blood panels, will be available via WHOOP in April. You can find links to imagery in our Digital Press Kit.
*The Women’s Health Specialized Panel will be available exclusively in the US at launch.
About WHOOP:
WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and long-term wellbeing. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Peer-reviewed research shows: that members who wear WHOOP daily increase their weekly exercise by more than 90 minutes, gain over two hours of additional sleep per week, and improve heart rate variability by 10%.
Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $400 million in venture capital, ships to 56 countries, and operates in six languages. Learn more at whoop.com and connect with WHOOP on Instagram, LinkedIn, X, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260310966566/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom